Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Xiaomi Shares Jump on Europe EV Expansion Plan 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
France Targets Shein, Temu With Fast-Fashion Fees 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Add as a preferred source on Google
LONDON and CARLSBAD, Calif., March 05, 2018 -- GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW’s Chief Executive Officer, will present at the Cowen and Company 38th Annual Health Care Conference on Monday, March 12, 2018, at 2:50 p.m. (EDT) at the Boston Marriott Copley Place in Boston, M.A.
A live audio webcast of the presentation will be available through GW’s corporate website in the investor relations section from the investor’s calendar of events page at www.gwpharm.com. A replay will be available soon after the live presentation.
About GW Pharmaceuticals plc and Greenwich Biosciences
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW, along with its U.S. subsidiary Greenwich Biosciences, is advancing an orphan drug program in the field of childhood-onset epilepsy with a focus on Epidiolex (cannabidiol), for which GW has submitted regulatory applications in the U.S. and Europe for the adjunctive treatment of Lennox-Gastaut syndrome and Dravet syndrome. The Company continues to evaluate Epidiolex in additional rare epilepsy conditions and currently has ongoing clinical trials in Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in numerous countries outside the United States and for which the company is now planning a US Phase 3 trial. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for epilepsy, gliobastoma, and schizophrenia. For further information, please visit www.gwpharm.com.
Enquiries:
| GW Pharmaceuticals plc | ||||
| Stephen Schultz, VP Investor Relations (U.S.) | 917 280 2424 / 401 500 6570 | |||
